1. Subcommittee G. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
2. Blood Pressure Lowering Treatment Trialist Collaboration. Effect of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–64.
3. Staessen JA. Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–15.
4. Messerli FH. Vasodilatalory oedema: a common side effect of antihypertensive therapy. Am J Hypertens 2001; 14: 978–9.
5. Uind-Johansen P. Hemodynamic effects of calcium antagonists in hypertension. In: Epstein M (editor): Calcium antagonists in clinical medicine (3rd edn). Philadelphia, Pennsylvania: Hanley & Belfus; 2002; pp. 315–35.
6. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipme GITS study: Intervention as a Goal m Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
7. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50: 560–86.
8. Papavassiliou MV, Vyssoulis GP, Karpanou EA et al. Side effecls of antihypertensive treatment with calciunn channel antagonists (abstract). Am J Hypertens 2001; 14: 114A.
9. Herbette LG, Vecchiarelli M, Leonard A. Lercanidipme: short plasma half-life, long duration of action. J Cardiovasc Pharm 1997; 29 (suppl. 1): S19–24.
10. Leonardi A, Poggesi E, Taddei C et al. In vitro calcium antagonist activity of Lercanidipme and its enantiomers. J Cardiovasc Pharm 1997; 29 (suppl. 1): S10–8.
11. Guarneri L, Sironi G, Angelico P et al. In vitro and in vivo vascular selectivity of Lercanidipine and its enantiomers. J Cardiovasc Pharm 1997; 29 (suppl. 1): S25–32.
12. Ambrosioni E, Circo A. Activity of Lercanidipme administered in single and repeated doses once daily as monitored over 24h in patients with mild to moderate essential hypertension. J Cardiovasc Pharm 1997; 29 (suppl. 1): S16–20.
13. Omboni S, Zanchetti A. Antihypertensive efficacy of Lercanidipine at 2,5, 5 and 10 mg m mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16: 1831–8.
14. Giorgio LADe, Orlandim F, Malasoma P, Zappa A. Double-blind, crossover study of Lercanidipme versus Amlodipine m the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 511–20.
15. McClsllan KJ, Jarvis B. Lercanidipme. A review of its use in hypertension. Drugs 2000; 60: 1123–40.
16. Veraari D, Virdis A, Ghiadom L et al. Lercanidipme restores nitric oxide availability in the forearm of essential hypertensive patients. J Hypertension 2002; 20 (suppl. 4): S270.
17 Venkata R. Usefulness of Lercanidipine, a new calcium antagonist for systemic hypertension. Am J Cardiol 2002; 89: 214–5.
18. Hollenberg NK. Observations on the safety of Lercanidipine, a novel CCB: adverse event data from placebo-controlled trials (poster). Annual Meeting, American Society of Hypertension; 15–18 May 2002; New York.
19. Nilsson S, Haugen GB. Volumetry in the evaluation of swelling in the ankle and foot. J Oslo City Hosp 1981; 31: 11–5.
20. Stranden E. A comparison between surface measurements and water displacement volumetry for the quantification of leg oedema. J Oslo City Hosp 1981; 31: 153–5.
21. Khiabani HZ, Arwar MO, Slranden E et al. Ooedema in the lower limb of patients with chronic critical limb ischaemia (CLI). Eur J Vase Endovasc Surg 1999; 17: 419–23.
22. Stranden E, Kroese AJ. Venodynamics in healthy subjects and in patients wilh venous dysfunction. Scope Phlebo Lymphology 1998; 5: 4–12.
23. Fogari R, Malarnani GD, Zoppi A et al. Comparative effect of Lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Cutr Ther Res 2000; 61: S50–62.
24. Leonetti G, Magnani B, Pessina AC et al. on behalf of the COHORT Study Group. Tolerability of long-term treatment with Lercanidipine versus Amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932–40.
25. Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens 2002; 15: 94S–7S.
26. Hamersvelt HW van, Kloke HJ, Jong DJ de et al. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens 1996; 14: 1041–5.
27 Salmasi AM, Belcaro G, Nicolaides AN. Impaired venoarteriolar reflex as a possible cause for nifedipine induced ankle ooedeina. Int J Csrdiol 1991; 30: 303–7.
28. Grassi G, Seravalle G, Turn C et al. Different behaviour of the sympathetic responses to acute and chronic blood pressure reductions induced by antihypertensive drugs. Eur Heart J 2001; 22: 109.
29. Fogari R, Corradi L, Mugellini A et al. Effects of different dihydropyridme calcium antagonists on plasma noerepinephrine in essential hypertension (abstract). Am J Hypertens 2002; 15: 8.
30. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775–9.

P.Lund-Johansen, E.Stranden, S.Helberg, T.Wessel-Aas,K.Risberg, P.K.Ronnevik, H.Istad, S. Madsbu